Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CSF3R |
Variant | N579Y |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | CSF3R N579Y lies within fibronectin type-III domain 5 of the Csf3r protein (UniProt.org). N579Y confers a gain of function to Csf3r as demonstrated by cytokine-independent growth and increased Erk1/2 and Stat3 phosphorylation in cultured cells (PMID: 36579444). |
Associated Drug Resistance | |
Category Variants Paths |
CSF3R mutant CSF3R act mut CSF3R N579Y |
Transcript | NM_000760.4 |
gDNA | chr1:g.36467951T>A |
cDNA | c.1735A>T |
Protein | p.N579Y |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047446753.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
NM_000760.4 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
XM_011540749.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
NM_156039.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
XM_005270493.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
XM_011540748.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
NM_000760.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
XM_011540749.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
XM_017000370.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
XM_005270493.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
NM_156039.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
NM_172313.2 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
NM_172313.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CSF3R N579Y | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) treatment inhibited colony formation and decreased viability of transformed cells expressing CSF3R N579Y in culture (PMID: 36579444). | 36579444 |